Silence Therapeutics plc
NASDAQ:SLNBiotechnology
+$0.19 today
- Market cap
- $936.18M
- Beta
- 1.48
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.80
Volume 1.47M
Average 0.31M
SLN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Silence Therapeutics plcNASDAQ: SLN
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.45M fell 10.7% year over year. Sequentially, it fell 66.4% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Stock-based compensation amounted to 1444.4% of revenue in FY2025, up 1420.3 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
Mixed currencies · from the cash flow
- Latest · FY2025
- 8.07M USD
- Year-over-year change
- —
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.07M | — |
| FY2024 | 2024-12-31 | 10.41M | -20.2% |
| FY2023 | 2023-12-31 | 13.05M | +2.9% |
| FY2022 | 2022-12-31 | 12.69M | +8.9% |
| FY2021 | 2021-12-31 | 11.65M | — |
Stock-Based Compensation vs competitors
How SLN compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Stock-based compensation amounts to 1556.3% of revenue for SLN, versus a peer median of 15.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $132.29M USD | +4.4% | +10.1% | 13.8% | |
| LTM Mar 2026 | $111.37M USD | -39.8% | -19.1% | 5.1% | |
| LTM Sep 2026 | $68.15M USD | +7.5% | -4.5% | 15.1% | |
| LTM Mar 2026 | $23.07M USD | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $21.73M USD | +42.8% | — | 30.3% | |
| LTM Mar 2026 | $14.34M USD | — | -14.0% | 1556.3% | |
| LTM Mar 2026 | $12.56M USD | +183.6% | +171.6% | — | |
| FY2025 | $7.68M USD | — | — | 41.2% | |
| LTM Mar 2026 | €2.03M EUR | -21.0% | — | 15.1% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding SLN) | — | +4.4% | -4.5% | 15.1% | |
Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · GBP | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (61.89M) | (50.33M) | (50.31M) | (28.92M) | (88.61M) |
| Depreciation & Amortization | 576.29K | 596K | 498K | 473.86K | 555K |
| Deferred Income Tax | 5.95M | 688K | 0 | 675.23K | 11K |
| Stock-Based Compensation | 11.65M | 12.69M | 13.05M | 10.41M | 8.07M |
| Change in Working Capital | 52.43M | (19.4M) | (11.66M) | (26.39M) | 10.16M |
| Accounts Receivables | 37.09M | (10.54M) | 314K | (722.38K) | 5.07M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 15.33M | (8.85M) | (11.98M) | (25.67M) | 5.09M |
| Other Non-Cash Items | 468.32K | (1.28M) | 9.07M | (10.3M) | 7.54M |
| Operating Cash Flow | 9.19M | (57.04M) | (39.35M) | (54.05M) | (62.27M) |
| Capital Expenditures | (1.8M) | (545K) | (45K) | (168.61K) | (55K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (19.95M) | (20.67M) | (111.21M) | (166.41M) |
| Sales of Investments | 13.5M | 0 | 36.18M | 0 | 118.48M |
| Other Investing Activities | (17.55K) | (372K) | 958K | 93.82M | 0 |
| Investing Cash Flow | 11.71M | (20.5M) | 16.43M | (17.55M) | (47.99M) |
| Debt Repayment | (284.77K) | 0 | (174K) | 0 | 0 |
| Common Stock Issued | 41.73M | 52.58M | 25.33M | 113.54M | 15K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 41.45M | 52.58M | 25.16M | 113.54M | 15K |
| Effect of Forex Changes | (141.71K) | (8.12M) | (3.02M) | 47.95K | 195K |
| Net Change in Cash | 62.2M | (33.08M) | (785K) | 41.98M | (110.05M) |
| Free Cash Flow | 7.39M | (57.59M) | (39.4M) | (54.22M) | (62.33M) |
Silence Therapeutics plc
NASDAQ:SLN
Intrinsic Alpha fair value
Locked
Current Price
$19.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.